| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | TRT Catalog |
| URL | trtcatalog.com/learn/fda-testosterone-descheduling-expanded-access (opens in a new tab) |
Specific Claim Evaluated
An FDA expert panel recommended removing testosterone's Schedule III controlled substance status and expanding FDA-approved indications to age-related low testosterone.
Primary Research Supporting or Contradicting the Claim
The subsequent Federal Register notice describes an FDA review of published literature and invites supplemental applications for a single, narrower indication (low libido in idiopathic hypogonadism), not a general age-related indication (U.S. Food and Drug Administration, 2026a).
Corrected Evidence-Based Interpretation
The December 2025 meeting was an FDA-convened panel discussion at which individual experts advocated these changes; it was not a chartered advisory committee vote. Controlled substance scheduling is determined through a separate DEA process. As of the article date, no change had occurred.
Rationale for Grade
The page correctly states that testosterone remained Schedule III and that indications had not changed. It presents the views of individual panelists as a formal panel recommendation, which overstates their regulatory weight. It also does not explain that rescheduling is outside FDA's sole authority. These are omissions of context rather than false statements.
References
- U.S. Food and Drug Administration. Potential new indication for testosterone replacement therapy. Federal Register. 2026;91 FR 21002. Document 2026-07615. Published April 20, 2026.
Supporting excerpt: "information in published literature that seems promising"